Crossbow arms itself with $80 million for mission to cure cancer

Boston, USA-based Crossbow Therapeutics, a biotech developing a new class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding round.

MPM BioImpact and Pfizer Ventures led the round, with participation from Polaris Partners, BVF Partners, Eli Lilly (NYSE: LLY), Mirae Asset Venture Investment, and Mirae Asset Capital.

The financing will allow Crossbow to advance the development of therapies that potently target peptide-loaded major histocompatibility complexes on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).